Long Duration High Frequency Ultrasound for the Treatment of Osteoarthritis
Condition(s) studied
Investigational drug(s) / intervention(s)
Sustained Acoustic Device with 2.5% Diclofenac Patch: Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3 megahertz(MHz) frequency and 0.132 Watts/cm\^2 with 2.5% Diclofenac patches.
Sustained Acoustic Device with 0% Diclofenac Patch: Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours with 0% diclofenac patches.
Intra articular injection: Single intraarticular injection of 1cc 40mg/cc triamcinolone acetonide
Study summary
The purpose of this study is to assess the ability of long-duration high-frequency continuous-wave therapeutic ultrasound to alleviate knee Osteoarthritis pain over an 12-week period. The primary objective of this study is to evaluate the analgesic effect of ultrasound treatment in subjects suffering from knee Osteoarthritis pain. Secondary objectives are to assess the ability of ultrasound treatment to improve joint function.
Eligibility
Primary outcome measure(s)
- Change in Pain Units on a Scale (0-10) 0 Being Least, 10 Being Worst Pain From Baseline — Through study completion, average of 12 weeks
Change in the self-described pain units on a scale by patient at baseline and post-treatment - Change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) — Through study completion, average of 12 weeks.
WOMAC questionnaire will be utilized (Western Ontario and McMaster Universities Arthritis Index) at baseline and post-treatment to calculate the change in scores. WOMAC was divided into 3 categories: pain, stiffness, function and total score. The pain category consists of five scores from 0 - 4, 0 being no pain 4 is worst pain possible, for a range of 0 - 20 points. The stiffness category consists of two scores from 0 - 4, 0 being no stiffness 10 is worst stiffness possible for a range of 0 - 8 points. The function score consists of 17 scores from 0 - 4, 0 being normal function and 10 is severely limited function, for a range of 0 - 68 points. Total score is the sum of pain, stiffness, and function scores (range of 0 - 96).
Trial sites (2)
| Facility | City | Region | Status |
|---|---|---|---|
| Orthopaedic Foundation | Stamford | Connecticut | |
| Cayuga Medical Center - Medical Pain Consultants | Dryden | New York |
More ZetrOZ, Inc. trials in the USA
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07515872 on ClinicalTrials.gov ↗ ← All trials in the USA